Related Experiment Video
Updated: Jun 12, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
[Effect of sorafenib combined with daunorubicin on K562 cell line]
Ruo-Zhi Xiao1, Li-Lin Wang, Xing-Xing Ruan
1Institute of Hematologic Diseases, SUN Yat-Sen University, Guangdong Province, China. ruozhi_xiao@yahoo.com
Abstract:
The aim of this study was to investigate the effect of sorafenib combined with daunorubicin on leukemic k562 cell line. The inhibitory effect of sorafenib alone and its combination with daunorubicin on K562 cell proliferation was detected by MTT method; the synergistic effect was measured by CDI (coefficient of drug interaction); the apoptosis of K562 cells was observed by flow cytometry with Hoechst 33258 staining. The results showed that the sorafenib alone or its combination with daunorubicin could significantly inhibit K562 cell proliferation and the combination of both drugs displayed synergistic effect on K562 cells, meanwhile the apoptotic cells increased. It is concluded that the combination of sorafenib and daunorubicin has a obviously synergistic inhibitory effect on leukemic cell line K562.
Insights
Sorafenib and daunorubicin show a synergistic effect, significantly inhibiting K562 leukemia cell proliferation and increasing apoptosis. This combination therapy offers a promising approach for treating K562 leukemia.
Area of Science:
- Pharmacology
- Cell Biology
- Oncology
Background:
- Leukemia, specifically the K562 cell line, remains a significant challenge in cancer therapy.
- Investigating novel drug combinations is crucial for overcoming drug resistance and improving treatment efficacy.
Purpose of the Study:
- To evaluate the combined effect of sorafenib and daunorubicin on K562 cell proliferation.
- To determine the synergistic interaction between sorafenib and daunorubicin.
- To assess the impact of this drug combination on K562 cell apoptosis.
Main Methods:
- Cell proliferation was assessed using the MTT assay.
- Synergistic drug interaction was quantified using the Coefficient of Drug Interaction (CDI).
- Apoptosis was analyzed via flow cytometry with Hoechst 33258 staining.
Main Results:
- Both sorafenib and daunorubicin individually inhibited K562 cell proliferation.
- The combination of sorafenib and daunorubicin demonstrated a significant synergistic inhibitory effect.
- Increased apoptosis was observed in K562 cells treated with the drug combination.
Conclusions:
- Sorafenib and daunorubicin exhibit a clear synergistic effect against the K562 leukemia cell line.
- The combination therapy enhances the inhibition of leukemia cell growth and promotes cell death.
- This combination warrants further investigation for potential clinical application in K562 leukemia treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...